About
- About Avecho
- Board & Leadership
TPM^® Technology
Portfolio
Invest
- Investor Centre
- Media Centre
Contact

Hit enter to search or ESC to close

Phosphagenics and Mylan Agree Settlement

December 19, 2018

Click here to read more

Post navigation

Voluntary Withdrawal from OTCQX

2019 Annual General Meeting Results

Related Posts

Positive Results for Phase II Topical CBD Osteoarthritis Study

March 29, 2022March 29, 2022

Phosphagenics Signs Japanese License Option Agreement and R&D Alliance

April 29, 2016

Entitlement Offer

April 3, 2023April 3, 2023

Recent Posts

MEDIA | Ausbiz
March 7, 2025
March 2025 | Investor Webinar
March 6, 2025
MEDIA | 180 Markets
March 5, 2025

Categories

Analyst Coverage
Company Announcement
Company Report
Investor Webinar
Media Coverage
Newsletter
Press Release
Uncategorised

About us

We see a future where more patients can get even more from their treatments through innovative delivery technologies.

Stay Posted

Stay informed about our latest news and developments.

Leave this field empty if you're human:

About Avecho

TPM^® Technology

Portfolio

Investor Centre
- Investor Centre
- Media Centre

© Copyright 2019 Avecho Biotechnology Ltd.